After exclusion of the potential confounding variable that is metastatic disease, these findings confirm that SUFU mutated patients tend to present with more events over the course of time (reduced EFS/PFS), but larger numbers and longer follow up would be needed to assess for statistically significant differences between the SUFU and PTCH1 versus non Gorlin MB patients. This evidence concerns the gene PTCH1 and metastatic neoplasm.